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MaOBJECTIVES This study hypothesized that regurgitation severity, as determined by using the regurgitant volume index,
would better delineate differential cardiac dysfunction in asymptomatic patients with moderate to severe aortic regur-
gitation (AR) and mitral regurgitation (MR).
BACKGROUND Frequent surveillance echocardiography is considered appropriate in asymptomatic patients with
moderate to severe AR and MR. However, the evidence to support this practice and to deﬁne the appropriate frequency is
limited.
METHODS This was an observational cohort study of consecutive patients with moderate to severe asymptomatic AR or
MR who underwent exercise echocardiography. Our cohort included 130 patients with moderate to severe asymptomatic
MR and 130 patients with moderate to severe asymptomatic AR who were matched according to age and regurgitant
volume index. All patients underwent yearly echocardiographic follow-up studies. Regurgitation severity was determined
according to regurgitant volume index, with a level $30 ml/m2 considered a marker of severe regurgitation.
RESULTS During follow-up, regardless of etiology, patients with severe regurgitation demonstrated increasing left
ventricular volume indexes (4.2  1.5 ml/m2 per year; p ¼ 0.01) and decreasing left ventricular ejection fractions (1.3 
0.4% per year; p ¼ 0.002). In patients with moderate regurgitation, left ventricular volumes and ejection fractions did
not signiﬁcantly change. In addition, patients with severe regurgitation experienced a similar drop in contractility
(end-systolic pressure/end-systolic volume ratio and single-beat pre-load recruitable stroke work) during follow-up
independent of regurgitation etiology. Contractility parameters did not change in patients with moderate regurgitation.
CONCLUSIONS These asymptomatic patients with moderate AR or MR had stable cardiac function during 3 years of
follow-up; thus, frequent echocardiography without a change in clinical status may not be necessary. In the setting of
severe regurgitation, further cardiac deterioration occurred at a similar rate and manner irrespective of whether the
dysfunction was related to AR or MR. (J Am Coll Cardiol Img 2015;8:14–23) © 2015 by the American College of
Cardiology Foundation.D etails regarding follow-up at appropriateintervals and the subsequent managementof asymptomatic patients with aortic regur-
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AB BR E V I A T I O N S
AND ACRONYM S
AR = aortic regurgitation
ESPVR = end-systolic
pressure–volume ratio
ESSm = meridional end-systolic
wall stress
LAV = left atrial volume
LV = left ventricular
LVEDV = left ventricular
end-diastolic volume
LVEDVI = left ventricular
end-diastolic volume index
LVESV = left ventricular
end-systolic volume
LVESVI = left ventricular
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15severe MR and AR demonstrate adverse remodeling
with increased left ventricular (LV) volumes and
decreased ejection fractions over time, the natural
history of patients with less severe regurgitation is
unclear (7,8). Furthermore, in the setting of the
same amount of regurgitation, an assessment for a
divergent decline in cardiac function according to
valve lesion has not been performed. Such an evalua-
tion would be clinically relevant because it would
better deﬁne which parameters should be monitored
and would more precisely determine the appropriate
timing for interval echocardiography. Therefore, we
investigated whether regurgitant volume would
inform the rate of differential decline in cardiac func-
tion in asymptomatic patients with moderate to
severe MR or AR.SEE PAGE 24
end-systolic volume index
METs = metabolic equivalents
MR = mitral regurgitation
PRSW = single-beat pre-load
recruitable stroke work
RVSP = right ventricular
lic pressureMETHODS
STUDY SAMPLE. This was an observational cohort
study of consecutive patients with moderate to se-
vere isolated asymptomatic AR or MR who underwent
exercise echocardiography at the Cleveland Clinic
between January 2007 and January 2012 (9,10). Pa-
tients with AR and MR were matched according to age
(within 5 years) and regurgitant volume index (within
5 ml/m2) by using a random number generator to
assure lack of bias. Because age is a strong predictor
of progression of any disease and has a profound
impact on cellular mechanisms that determine
myocardial response to overload (11), we used age to
match AR and MR patients to exclude the effect of
this factor. All patients had preserved LV size and
function according to valvular heart disease guide-
lines (2). These included the following: for AR, LV
ejection fraction >50%, LV end-diastolic diameter
<70 mm, LV end-systolic diameter <50 mm, or LV
end-systolic diameter/body surface area <25 mm/m2;
and for MR, LV ejection fraction >60% or LV end-
systolic diameter <45 mm. All patients underwent
at least 1 yearly echocardiographic follow-up study,
according to the guidelines. We excluded patients
with more than mild concomitant valvular disease,
atrial ﬁbrillation or ﬂutter, and stress-induced myo-
cardial ischemia or scar. All patients underwent
symptom-limited exercise treadmill testing using
standard treadmill protocols with 12-lead electro-
cardiography monitoring. The maximal exercise
tolerance was expressed as estimated metabolic
equivalents (METs). Predicted exercise capacity was
calculated in accordance with described nomograms
(predicted METs; in male subjects, 18 – [0.15  age]; infemale subjects, 14.7 – [0.13  age]) (12), and
percent predicted METs were described as
the difference between actual and predicted
METs divided by predicted METs. The pro-
tocol was approved by the Cleveland Clinic
Institutional Review Board.
ECHOCARDIOGRAPHIC ASSESSMENT. Trans-
thoracic echocardiography was performed by
experienced sonographers using a commer-
cially available ultrasound machine (Vivid 7
or Vivid 9, GE Vingmed, Horten, Norway;
Sonos 5500 or iE33, Philips Healthcare, And-
over, Massachusetts). Measurements and re-
cordings were obtained according to the
American Society of Echocardiography rec-
ommendations (13). Left ventricular end-
diastolic volume (LVEDV), left ventricular
end-systolic volume (LVESV), left atrial vol-
ume (LAV), and LV ejection fraction were
calculated by using the biplane Simpson disk
method using 2-dimensional images and
indexed to body surface area. The LV mass
was estimated from the formula of Devereux and
Reichek (14). Right ventricular systolic pressure
(RVSP) was estimated from the maximal continuous
wave Doppler velocity of the tricuspid regurgitant jet
by using a systolic transtricuspid pressure gradient
calculated according to the modiﬁed Bernoulli equa-
tion. Quantiﬁcation of regurgitant volume was per-
formed by using the quantitative Doppler method: the
difference between valve stroke volume and systemic
stroke volume (15). LV meridional end-systolic wall
stress (ESSm), as a measure of LV afterload, was
calculated from the formula of Grossman et al. (16).
Because the averaged body surface area in our pop-
ulation was 2.0 m2 and because the cutoff value for
severe regurgitant volume is 60 ml for both AR and
MR according to the current guidelines (15), we
selected the indexed value of $30 ml/m2 to indicate
severe valve regurgitation to eliminate the impact of
body size on gradation of regurgitant severity.
CONTRACTILITY ASSESSMENT. Two markers of con-
tractility were used: end-systolic pressure–volume
ratio (ESPVR) (a surrogate for LV systolic elastance)
and single-beat pre-load recruitable stroke work
(PRSW). End-systolic pressure was calculated using
estimations from the previous study (i.e., end-systolic
pressure¼0.9 brachial systolic pressure) (17). ESPVR
and PRSW were calculated using the following for-
mulas: ESPVR ¼ end-systolic pressure/left ventricular
end-systolic volume index [LVESVI]; PRSW ¼ (stroke
volume  mean aortic pressure)/(0.28  LVEDV þ
0.28  LV wall volume) (18,19). Because ESPVR and
systo
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16PRSW differ in their sensitivities to contractility and
LV size, ﬁndings of their change occurring in the same
direction reinforces the conclusion of true change in
contractility (20).
VALIDATION OF ECHOCARDIOGRAPHIC PARAMETERS.
To validate regurgitant volume, LVEDV, and LVESV,
we used data from 30 patients with AR and MR who
also had a cardiac magnetic resonance (CMR) study
performed to assess the severity of valve disease. The
details of these measurements have been described
previously (21,22). In brief, velocity-encoded CMR
was performed. The integral of ﬂow rate was calcu-
lated for backward ﬂow during diastole (regurgitant
volume) using commercially available softwareBaseline Clinical Variables
Mitral
Regurgitation
(n ¼ 130)
Aortic
Regurgitation
(n ¼ 130) p Value
54  11
(52, 44–61)
54  11
(53, 40–64)
0.83
88 (68) 100 (77) 0.12
ce area, m2 1.9  0.2
(1.9, 1.7–2.1)
2.0  0.2
(2.0, 1.8–2.1)
0.08
9 (7) 10 (8) 0.82
ion 54 (42) 75 (58) 0.01
esterolemia 49 (38) 55 (42) 0.49
56 (43) 70 (54) 0.10
ker 46 (35) 44 (34) 0.84
hannel blocker 18 (14) 22 (17) 0.62
apacity (METs) 10.2  2.6
(10.0, 8.0–11.5)
10.5  2.8
(10.5, 8.5–13.0)
0.39
ed METs 117  26
(117, 99–129)
114  25
(110, 92–126)
0.47
graphy
stolic LV volume
x, ml/m2
68  22
(65, 52–85)
78  33
(77, 60–92)
<0.001
tolic LV volume
x, ml/m2
25  8
(24, 19-30)
32  11
(32, 25–38)
<0.001
index, g/m2 117  49
(111, 80–141)
132  37
(128, 106–154)
0.003
ion fraction, % 63  3
(63, 61–66)
58  3
(58, 54–62)
<0.001
me index, ml/m2 45  18
(43, 34–52)
33  13
(32, 23–39)
<0.001
tant volume index, ml/m2 28  7
(28, 21–34)
27  7
(27, 21–32)
0.52
egurgitation, % 62 (48) 50 (38) 0.15
mm Hg/ml/m2 5.1  2.0
(4.9, 3.6–6.2)
4.2  1.7
(3.7, 3.0–4.7)
<0.001
$m/ml 48  19
(46, 36–57)
38  9
(38, 32–44)
<0.001
dyne/cm2 70  27
(66, 53–85)
77  22
(76, 61–90)
0.04
m Hg 28  7
(28, 23–33)
22  8
(21, 17–27)
<0.001
ean  SD, median (interquartile range), or n (%).
¼ angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker;
nd-systolic pressure–volume ratio; ESSm ¼ meridional end-systolic wall stress;
rial; LV ¼ left ventricular; METs ¼ estimated metabolic equivalents; PRSW ¼ single-
d recruitable stroke work; RVSP ¼ right ventricular systolic pressure.(Philips Extended MR WorkSpace, Philips Health-
care). The CMR measurements were performed
independently and without the knowledge of echo-
cardiographic ﬁndings.
STATISTICAL ANALYSIS. Data are presented as mean
 SD if the Kolmogorov-Smirnov test showed a
normal distribution. Median and interquartile ranges
are also reported. The Student t test was used to
compare continuous variables, and the chi-square
test was applied to compare categorical variables. To
assess the differences in cardiac size and function
between groups, a linear mixed effects model was
applied, with unstructured covariance for random
effects by using standard statistical software (SPSS
version 20.0, IBM SPSS Statistics, IBM Corporation,
Armonk, New York) (23,24). We used regurgitation
severity (moderate vs. severe) and regurgitation type
(MR vs. AR) as factors and time after initial echocar-
diographic assessment as a covariate, as well as their
ﬁrst-degree interactions (severity  time, severity 
regurgitation type, and time  severity, with the
signiﬁcance of corresponding parameter estimates
reported in the Results). Interobserver and intra-
observer variability was examined for left ventricular
end-diastolic volume index (LVEDVI), LVESVI, ejec-
tion fraction, ESPVR, and PRSW. Measurements were
performed by 1 observer in a group of 20 randomly
selected subjects and then repeated on 2 separate
days by 2 observers who were unaware of the mea-
surements of the others and of the study time point.
Agreement between echocardiography and CMR was
assessed using Pearson’s correlation coefﬁcient and
Bland-Altman analysis. Statistical signiﬁcance was
deﬁned by p < 0.05.
RESULTS
PATIENT SAMPLE. Our initial cohort comprised 698
patients undergoing exercise echocardiography with
left-side valvular disease and preserved ejection
fraction. After the exclusion of 319 patients without
follow-up, we successfully matched 130 patients with
moderate to severe asymptomatic MR (54  11 years;
68% men) to 130 patients with moderate to severe
asymptomatic AR (54  11 years; 77% men) (Online
Figure 1). Patients were classiﬁed according to
regurgitant volume into a moderate group (regur-
gitant volume index <30 ml/m2) or a severe group
(regurgitant volume index $30 ml/m2).
The clinical features of the study patients (Table 1)
were typical of an asymptomatic AR and MR popula-
tion. Patients were asymptomatic and with preserved
exercise capacity (% predicted METs: 117  26% for
MR and 114  25% for AR; p ¼ 0.47). During the
TABLE 2 Clinical Outcomes During Follow-Up
Aortic Regurgitation Mitral Regurgitation
Echo Death Operation
Lost to
Follow-Up Echo Death Operation
Lost to
Follow-Up
Year 0 130 (100) 0 0 0 130 (100) 0 0 0
Year 1 130 (100) 0 8 (6) 0 130 (100) 0 25 (19) 0
Year 2 122 (94) 0 8 (6) 43 (33) 105 (81) 0 19 (15) 20 (15)
Year 3 71 (55) 0 9 (7) 22 (17) 66 (51) 0 9 (7) 14 (11)
Values are n (%).
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17echocardiographic follow-up of 3 years, valve surgery
was performed in 53 (41%) patients with MR and in 25
(19%) patients with AR (Table 2). During that period, 5
(7%) patients with MR and 3 (4%) patients with AR
exhibited worsening of regurgitation (from moderate
to severe). In this population, 75% (6 of 8) patients
underwent valve surgery (2 patients at 2 years’ follow-
up and 4 patients at 3 years’ follow-up). The decision
for valve surgery was driven by both the occurrence of
symptoms and the worsening of regurgitation in all
patients with moderate regurgitation at baseline. In
a subset of patients who underwent open heart sur-
gery, no signiﬁcant coronary artery disease was found
according to pre-operative coronary angiography. In
patients with AR, at echocardiography before surgery,
LVEDVI was 95  32 ml/m2, LVESVI was 42  14 ml/m2,
and LV ejection fraction was 58  4%. Corresponding
values for MR patients were 72  22 ml/m2, 27  9
ml/m2, and 60  4% for LVEDVI, LVESVI, and LV
ejection fraction, respectively.
ASSESSMENT OF ECHOCARDIOGRAPHIC LV VOLUMES
AND EJECTION FRACTION. As expected, on the basis
of parameter estimates obtained using the mixed
effects model, LVEDVI was larger in patients with
severe regurgitation (p < 0.001) and in patients with
AR (p < 0.001) even at the beginning of follow-up.
LVEDVI in patients with severe regurgitation in-
creased at a rate of 4.2  1.5 ml/m2 per year (p ¼ 0.01)
independent of the type of lesion. In patients with
moderate regurgitation, there was no signiﬁcant
change in LVEDVI over time despite the fact that AR
patients had an increased LVEDVI at baseline
(Figure 1A). Similarly, again on the basis of the mixed
effects model, LVESVI was larger in patients with
more severe regurgitant lesions (p ¼ 0.002) and in
patients with AR (p < 0.001) at the beginning of
follow-up. Although LVESVI in patients with severe
regurgitation increased at a mean rate of 2.5  0.7
ml/m2 per year (p ¼ 0.001) independent of the type of
lesion, there was no signiﬁcant change in LVESVI in
patients with moderate regurgitation (Figure 1B).
Finally, LV ejection fraction was also lower in pa-
tients with AR (p < 0.001), although there was no
relationship between regurgitation severity and LV
ejection fraction at the beginning of follow-up
(p ¼ 0.16). LV ejection fraction remained unchanged
in patients with moderate regurgitation, but it de-
creased at a rate of 1.3  0.4% per year (p ¼ 0.002)
in patients with severe regurgitation (Figure 1C).
ASSESSMENT OF ECHOCARDIOGRAPHIC LAV INDEX
AND RVSP. As expected, on the basis of the mixed
effects model, LAV index in patients with MR was
larger by 15  3 ml/m2 than in patients with AR(p < 0.001) at the beginning of follow-up. LAV index
signiﬁcantly increased over time in both AR and MR
(p < 0.01 for both), however, at a rate that was higher
in MR than in AR (3.7  1.5 ml/m2 per year vs. 1.1  0.7
ml/m2 per year; p ¼ 0.03 for comparison). This in-
crease was independent of the regurgitation severity
(Figure 2A). On the basis of the mixed effects model,
RVSP was also higher in patients with MR by 6.2  0.7
mm Hg (p < 0.001) at the beginning of follow-up.
There was a borderline trend toward increased RVSP
in patients with moderate regurgitation (0.7  0.4
mm Hg per year; p ¼ 0.09). RVSP signiﬁcantly
increased in patients with severe regurgitation (1.2 
0.6 mm Hg per year; p ¼ 0.03), but there was no dif-
ference in the RVSP increase between AR and MR
patients (Figure 2B). Finally, on the basis of the mixed
effects model, LV mass index was larger in patients
with AR and severe regurgitation by 29 g/m2 and
16 g/m2 at the beginning of follow-up (p < 0.001),
respectively. No signiﬁcant change was noted during
follow-up (Figure 2C).
ASSESSMENT OF CONTRACTILITY. On the basis of
the mixed effects model, ESPVR was signiﬁcantly
lower (indicating lower contractility) in patients with
AR at the beginning of follow-up (p < 0.001). In all
patients with moderate regurgitation, ESPVR re-
mained stable. However, patients with severe regur-
gitation had a continuous drop in ESPVR throughout
follow-up (p ¼ 0.002) (Figure 3A). Similarly, on the
basis of the mixed effects model, patients with AR
had lower PRSW (p < 0.001) with a more dramatic
difference in the setting of moderate regurgitation at
the beginning of follow-up (p ¼ 0.04). Patients with
moderate regurgitation of any etiology had stable
PRSW over time (p ¼ 0.2), whereas patients with se-
vere regurgitation experienced a continuous drop in
PRSW (p ¼ 0.044) (Figure 3B). In summary, patients
who have AR seemed to have lower baseline
contractility compared with patients who have MR. In
addition, patients with severe regurgitation experi-
enced a similar drop in contractility independent of
the etiology for regurgitation. On the basis of the
mixed effects model, ESSm (afterload) was larger in
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FIGURE 1 LVEDVI, LVESVI, and LVEF
Follow-up data for the (A) left ventricular end-diastolic volume index (LVEDVI), (B) left ventricular end-systolic volume index (LVESVI), and
(C) left ventricular ejection fraction (LVEF). Error bars show 1 SEM. AR ¼ aortic regurgitation; MR ¼ mitral regurgitation.
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FIGURE 2 LAVI, RVSP, and LV Mass Index
Follow-up data for the (A) left atrial volume index (LAVI), (B) right ventricular systolic pressure (RVSP), and (C) left ventricular (LV) mass index.
Error bars show 1 SEM. Abbreviations as in Figure 1.
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FIGURE 3 Left Ventricular ESPVR, Single-Beat PRSW, and ESSm
Follow-up data for the (A) end-systolic pressure–volume ratio (ESPVR), (B) single-beat pre-load recruitable stroke work (PRSW), and
(C) the end-systolic meridional wall stress (ESSm). Error bars show 1 SEM. Abbreviations as in Figure 1.
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TABLE 3 Intraobserver and Interobserver Variability of Echocardiographic Parameters
LVEDVI
(ml/m2)
LVESVI
(ml/m2)
LVEF
(%)
ESPRV
(mm Hg/ml/m2)
PRSW
(g $ m/ml)
Mean 69  18 30  10 56  12 4.3  1.6 39  12
Intraobserver variability
Mean absolute difference 2  2 3  2 4  3 0.4  0.3 4  3
Mean relative difference, % 2  2 8  6 8  9 9  7 10  9
Correlation 0.99 0.94 0.89 0.95 0.91
Interobserver variability
Mean absolute difference 5  2 2  2 4  4 0.4  0.6 4  3
Mean relative difference, % 7  4 8  9 6  6 9  12 10  7
Correlation 0.95 0.95 0.89 0.96 0.93
Values are mean  SD or %. Correlation is represented by correlation coefﬁcient (r).
LVEDVI ¼ left ventricular end-diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVESVI ¼ left
ventricular end-systolic volume index; other abbreviations as in Table 1.
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21patients with AR by 5.1 kdyne/cm2 at the beginning of
follow-up (p ¼ 0.014). There was a borderline trend
toward increased ESSm in AR and MR independent of
the severity (1.3  0.6 kdyne/cm2 per year; p ¼ 0.06)
(Figure 3C).
OBSERVER VARIABILITY. Interobserver and intra-
observer variabilities are reported in Table 3. Satis-
factory intraobserver and interobserver agreements
were found for these traditional systolic parameters
on echocardiogram.
ACCURACY OF REGURGITANT AND LV VOLUME
MEASUREMENTS. Reasonable correlations between
echocardiography and CMR values of regurgitant vol-
ume (r ¼ 0.86, p < 0.001), LVEDV (r ¼ 0.84, p < 0.001),
and LVESV (r ¼ 0.86, p < 0.001) were noted. Echo-
cardiography measurements slightly underestimated
LV volumes and overestimated regurgitant volume
(Online Figure 2).
DISCUSSION
The present study assessed the impact of regurgitant
lesion severity and location on cardiac function dur-
ing a 3-year period. Our results evaluated the impor-
tance of follow-up echocardiography in severe
regurgitant valve disease. According to the recent
American College of Cardiology/American Heart As-
sociation guidelines (5), the clinician must know the
size and function of the left ventricle and pulmonary
artery pressure in valve disease. Despite similar
amounts of regurgitation, patients with MR had a
larger increase in RVSP, whereas patients with AR
had more ventricular dilation (excluding LVEDVI).
However, in patients with moderate AR and MR,
measures of LVESVI remained stable over our follow-
up period, indicating effective adaptive responses.
In contrast, once AR or MR had become severe,
there was progressive LV dilation with associated
increasing pulmonary systolic pressures. These
changes occurred at a similar rate regardless of
whether the underlying lesion was MR or AR.
NATURAL HISTORY OF MR AND AR. In chronic AR
and MR, similar regurgitation volume causes
different pathophysiological responses. Recent
studies have shown that for the same amount of
regurgitation, LV volumes and mass are higher in AR
(25), and thus for similar end-systolic pressures, one
can expect that contractility in AR is lower than in MR
for any given level of regurgitant volume. Conversely,
why the contractility decrease in moderate AR may be
present but remains stable is unclear. One possible
explanation is the different pattern of myocardial
hypertrophy. In AR, the regurgitant volume creates
both a volume and pressure overload of the leftventricle; thus, wall stress may theoretically be
higher in AR than in MR (26). These different loading
conditions in MR and AR create 2 different types of
ventricular (and myocyte) hypertrophy. In MR, there
is an enlarged, thin-walled left ventricle in which the
mass to volume ratio is decreased (27), but in AR, the
mass to volume ratio is normal (28,29). This different
pattern may be more protective of contractility
decreases in AR than in MR.
An understanding of the natural history of chronic
AR and MR is an essential part of any management
plan. Pre-operative LV function and its early post-
operative response (30–32) in severe, advanced
symptomatic (stage D) AR and MR have been well
described. However, few data are available to inform
the progression of LV function changes in asymp-
tomatic (stage C) chronic AR and MR that does not yet
require surgery. In the present study, we used 3 years
of follow-up data in patients with MR and AR to show
widely different LV geometry and contractility
changes depending on regurgitation severity. We
found that LV geometry and contractility changes
remained stable over time in moderate regurgitant
lesions. In contrast, LV geometry and contractility
continuously worsened in patients with both severe
AR and MR. The earlier premise was that AR and MR of
moderate to severe grade tends to progress, leading to
a worsening of hemodynamic status and ultimately to
clinical symptoms. Accordingly, previous guidelines
(4) recommended “.repeat echocardiography at
yearly intervals in patients with moderate MR,” and
recent guidelines also recommend that patients with
moderate severity should be followed up every 1 to
2 years (5). However, our data suggest that moderate
regurgitation, at least in this population, remained
stable during 3 years of follow-up. Although a major-
ity of patients with moderate regurgitation did
not exhibit a signiﬁcant progression of either
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22regurgitation severity or LV impairment, the initial
moderate regurgitation in a small percent of patients
worsened during follow-up, which led to surgery in
most patients. However, all patients who experienced
worsening of regurgitation had a parallel develop-
ment of symptoms. Thus, careful assessment of
symptoms in patients with moderate regurgitation is
even more relevant if one opts not to perform routine
yearly echocardiographic follow-up evaluations.
PROGRESSIVE CONSEQUENCES OF MR AND AR. In
general, both MR and AR increase LV pre-load and
afterload, with subsequent increases in LV diastolic
pressures and eventual LV dysfunction (30,33).
By matching patients according to the regurgitant
volume, our data provide further insight into the nat-
ural history of AR and MR. Initially, compensatory
mechanisms of the moderate AR and MR are distinct
but likely efﬁcient over many years given the stability
that we have shown. However, once a regurgitant
volume threshold is exceeded, a more rapid decline
occurs. Speciﬁcally, when the regurgitant volume is
>30 ml/m2, progressive deterioration in the coming
years can be expected. Because this more rapid decline
is not lesion speciﬁc, we speculate that an inﬂection
point has been reached which represents the failure
of compensatory mechanisms and the beginning
of adverse afterload mismatch. This hypothesis, in
conjunction with the data that we have presented,
underscores the importance of regurgitant volume to
inform the expected clinical course of patientswithMR
or AR. Increasing LV size may be related to increasing
volume overload (due to increases in regurgitant vol-
ume), development of contractile dysfunction, or
intrinsic increase of the afterload. However, MR and
AR severity were largely stable in our patients during
follow-up and the blood pressure of our patients was
well controlled, with the majority of our patients
receiving afterload-reducing agents. Thus, the likely
culprit of deleterious and continuous LV remodeling is
eventual development and worsening of myocardial
dysfunction. In contrast, some impact of worsening of
pressure/volume overload cannot be excluded, as
progressive remodeling of any cause leads to a vicious
cycle of further cardiac overload and dilation.
CLINICAL IMPLICATIONS. Despite expert opinion,
evidence to support frequent surveillance echocar-
diography in asymptomatic patients with moderate
AR or MR is not available. Asymptomatic patients
with chronic isolated moderate AR or MR in our study
population remained stable at the 3-year follow-up. If
no changes in symptoms or physical ﬁndings occur,
there is less necessity of yearly echocardiographic
follow-up. Conversely, echocardiography as frequentas once a year may be warranted given the expected
progressive adverse remodeling in asymptomatic pa-
tients with severe AR. Likewise, asymptomatic pa-
tients with severe MR who do not undergo surgery
may beneﬁt from annual echocardiography.
STUDY LIMITATIONS. This was an observational
study conducted at a large tertiary care center that
included a selected population (with preserved LV
function) of patients with asymptomatic AR and MR.
Because there are potential selection and referral
biases in this study, these ﬁndings cannot be extrap-
olated to patients with AR or MR and signiﬁcant
concomitant valve lesions. We are unable to extend
our observations for follow-up periods that exceed 3
years. Although all patients had a stress test negative
for ischemia, a normal ejection fraction, and preserved
exercise capacity, we were unable to completely
exclude the inﬂuence of coronary artery disease. The
present study should be considered as hypothesis
generating, and larger prospective, multicenter
studies are warranted. We were unable to assess
whether LV remodeling was worse in the setting of
larger regurgitant volume (e.g., >50 ml/m2) because
the number of patients with large regurgitant volume
was limited. Because <10% of patients had repeat
stress echocardiograms, we did not have enough data
to report on capacity changes during follow-up.
Regurgitation severity was also measured on the ba-
sis of echocardiographic parameters, and these have
inherent measurement variability. As acknowledged,
a weakness of our study is the lack of direct mea-
surements of LV structure and function. Finally, we
were unable to obtain the diastolic wall stress to assess
the dilation of LV size in this population.
CONCLUSIONS
We have shown that regurgitant volume informs the
natural history of asymptomatic patients with chronic
AR and MR. With a similar moderate regurgitant
volume, patients with MR had increased LAV and
RVSP, whereas AR patients had increased LV volumes
and decreased contractility. In all of these asymp-
tomatic patients, echocardiographic parameters were
stable during the 3-year follow-up. In contrast, with
similar severe regurgitant volumes, progressive car-
diac dysfunction ensued at a similar rate and in a
similar manner regardless of the etiology for regur-
gitation. These data may endorse echocardiography
studies at less frequent intervals in stable patients
with moderate MR and AR (as assessed according to
regurgitant volume). However, our study was on the
basis of a short-term follow-up, with some patients
with moderate regurgitation showing worsening.
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23Larger prospective studies are needed to verify the
appropriate interval of echocardiographic follow-up
in this cohort.
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